UNSPSC 51412011: Nanterinone

This classification denotes a phosphodiesterase inhibitor with the molecular formula C15H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1S169L7KAV, chemically known as 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-quinolone but generally known as nanterinone, which bears US NIH Compound Identifier 71305. European Medicines Agency schedules Nanterinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09150MIG.

UNSPSC 51412011 Nanterinone, a Commodity code, encompasses advanced life support and emergency medications that state and local governments procure for fire rescue operations, hospital systems, and public health programs. The code covers specific injectable pharmaceuticals such as epinephrine, labetalol, adenosine, and diltiazem—critical agents for emergency medical response—sourced through sealed competitive bidding, cooperative purchasing agreements, and multi-source pharmaceutical frameworks. State and local issuing bodies soliciting under this code include municipal fire departments, state health agencies, and multistate purchasing cooperatives that aggregate demand across participating jurisdictions to secure competitive pricing and supply chain stability.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of labetalol HCI 100mg vials, 1,810 units of epinephrine 1:10,000 injections, 330 units of adenosine 6mg vials, and 1,020 units of diltiazem 25mg vials, with an estimated contract value of $40,000, a one-year initial term, and renewal options; the bid closed April 8, 2026, with a 5 percent bid discount sheltered for Small Local Business Enterprises. The Texas Health and Human Services Commission issued an RFI in April 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory state-level procurement activity upstream of formal solicitation. The Minnesota Department of Administration, through the Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) serving state and local facilities across Minnesota and Oregon, requiring vendors to distribute through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing weighted at 75 percent of evaluation and contract awards effective July 1, 2026.